Neuroendocrine cell hyperplasia of infancy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neuroendocrine cell hyperplasia of infancy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia https://clinicaltrials.eu/trial/study-on-the-effects-of-methylprednisolone-in-infants-with-neuroendocrine-cell-hyperplasia/ Wed, 29 Apr 2026 14:28:23 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-methylprednisolone-in-infants-with-neuroendocrine-cell-hyperplasia/ This clinical trial is focused on studying a rare lung condition called Neuroendocrine Cell Hyperplasia of Infancy (NEHI). NEHI is a disease that affects infants and involves an overgrowth of certain cells in the lungs, which can lead to breathing difficulties. The study will use a medication called Methylprednisolone, which is a type of steroid that can help reduce inflammation in the body. The medication will be given as a powder that is mixed into a solution and then injected into the bloodstream through a vein.

The purpose of the study is to evaluate how effective Methylprednisolone is in reducing the need for oxygen therapy in infants with NEHI over a period of 18 months. Participants in the study will receive treatment with Methylprednisolone for six months. The study will also involve monitoring the infants’ breathing and overall health to see if there are improvements in their condition. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, researchers will track various health outcomes, such as the number of children who still need oxygen therapy after 18 months, and any changes in their breathing patterns. The study will also look at the impact of the treatment on the quality of life for both the children and their families. Safety will be closely monitored, including any unexpected hospital visits or changes in blood pressure. The study aims to provide valuable information on the potential benefits of Methylprednisolone for infants with NEHI.

]]>